玻璃体腔注射康柏西普对眼底病患者裸眼视力及黄斑中心凹视网膜厚度的影响分析

Analysis of the Effect of Intravitreal Injection of Conbercept on the Naked Eye Visual and the Central Macular Thickness in Patients with Ophthalmic Fundus Disease

目的探讨玻璃体腔注射康柏西普在眼底病患者中的应用价值.方法将2019年6月—2020年10月该院收治的78例眼底病患者纳入该次研究,按照随机数字表法分为对照组39例与研究组39例.对照组采用玻璃体腔注射曲安奈德治疗,研究组采用玻璃体腔注射康柏西普治疗,两组患者均持续治疗3个月.对比分析两组治疗前后裸眼视力、黄斑中心凹视网膜厚度(central macular thickness,CMT)、眼压值以及并发症发生情况.结果治疗前,两组裸眼视力、CMT、眼压值比较,组间差异无统计学意义(P>0.05);治疗1周、1、3个月,研究组裸眼视力(0.30±0.10)、(0.39±0.13)、(0.42±0.14)均高于对照组,CMT(278.41±40.60)μm、(240.15±37.28)μm、(231.56±34.51)μm均小于对照组,眼压值(15.93±3.58)mmHg、(16.14±3.72)mmHg、(16.73±3.84)mmHg均低于对照组,组间差异有统计学意义(P<0.05).两组并发症发生率比较,研究组的5.13%低于对照组的20.51%,差异有统计学意义(P<0.05).结论玻璃体腔注射康柏西普能够有效提高眼底病患者的裸眼视力,改善CMT,且对眼压影响较小,安全可靠.

Objective To explore the application value of intravitreal injection of Conbercept in patients with ophthalmic fundus disease.Methods The 78 patients with fundus disease admitted to the hospital from June 2019 to October 2020 were included in the study,and were divided into a control group of 39 cases and a study group of 39 cases according to the random number table method.The control group was treated with intravitreal injection of triamcinolone acetonide,and the study group was treated with intravitreal injection of conbercept,both groups of patients continued treatment for 3 months.The uncorrected visual acuity,central macular thickness(CMT),intraocular pressure value before and after treatment and complications of the two groups were compared and analyzed.Results Before treatment,there was no statistically significant difference between the two groups of naked eyesight,CMT,and intraocular pressure(P>0.05);after treatment for 1 week,1 and 3 months,the naked eye visual(0.30±0.10),(0.39±0.13),(0.42±0.14)of the study group were higher than those of the control group,CMT(278.41±40.60)μm,(240.15±37.28)μm,(231.56±34.51)μm were all smaller than those of the control group,the intraocular pressure value(15.93±3.58)mmHg,(16.14±3.72)mmHg,(16.73±3.84)mmHg were all lower than those of the control group,and the differences between the groups were statistically significant(P<0.05).Comparing the incidence of complications between the two groups,5.13%in the study group was lower than 20.51%in the control group,and the difference was statistically significant(P<0.05).Conclusion Intravitreal injection of Conbercept can effectively improve the naked eye visual of patients with ophthalmic fundus disease,improve CMT,and have a small impact on intraocular pressure,which is safe and reliable.